Lagoda Investment Management L.P. reduced its position in Intrexon Corporation (NYSE:XON) by 49.2% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 211,132 shares of the biotechnology company’s stock after selling 204,758 shares during the period. Intrexon Corporation comprises about 1.9% of Lagoda Investment Management L.P.’s portfolio, making the stock its 16th biggest holding. Lagoda Investment Management L.P. owned about 0.18% of Intrexon Corporation worth $5,086,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Pacer Advisors Inc. raised its position in Intrexon Corporation by 21.6% during the first quarter. Pacer Advisors Inc. now owns 7,352 shares of the biotechnology company’s stock worth $146,000 after acquiring an additional 1,305 shares during the period. SG Americas Securities LLC acquired a new position in Intrexon Corporation during the first quarter worth $164,000. Federated Investors Inc. PA acquired a new position in Intrexon Corporation during the second quarter worth $172,000. Cullinan Associates Inc. acquired a new position in Intrexon Corporation during the second quarter worth $201,000. Finally, John G Ullman & Associates Inc. acquired a new position in Intrexon Corporation during the second quarter worth $212,000. Hedge funds and other institutional investors own 82.11% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This story was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this story on another site, it was stolen and republished in violation of U.S. & international copyright legislation. The legal version of this story can be read at https://www.watchlistnews.com/lagoda-investment-management-l-p-has-5-09-million-position-in-intrexon-corporation-xon/1610233.html.

In other news, COO Andrew J. Last purchased 2,000 shares of the business’s stock in a transaction dated Monday, August 14th. The stock was acquired at an average price of $19.99 per share, with a total value of $39,980.00. Following the purchase, the chief operating officer now directly owns 2,000 shares of the company’s stock, valued at approximately $39,980. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Robert B. Shapiro purchased 2,850 shares of the business’s stock in a transaction dated Tuesday, August 22nd. The shares were purchased at an average cost of $17.50 per share, with a total value of $49,875.00. Following the purchase, the director now directly owns 43,157 shares in the company, valued at $755,247.50. The disclosure for this purchase can be found here. Insiders have bought a total of 144,569 shares of company stock valued at $2,719,429 in the last ninety days. Corporate insiders own 55.10% of the company’s stock.

A number of research firms have weighed in on XON. BidaskClub upgraded shares of Intrexon Corporation from a “sell” rating to a “hold” rating in a research report on Thursday, June 22nd. Northland Securities set a $30.00 price objective on shares of Intrexon Corporation and gave the stock a “buy” rating in a research report on Monday, August 7th. Finally, Zacks Investment Research cut shares of Intrexon Corporation from a “hold” rating to a “sell” rating in a research report on Thursday, July 13th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company’s stock. Intrexon Corporation currently has an average rating of “Hold” and an average price target of $41.00.

Intrexon Corporation (NYSE XON) traded up 1.97% during midday trading on Thursday, hitting $20.21. 459,098 shares of the stock were exchanged. Intrexon Corporation has a one year low of $17.03 and a one year high of $32.90. The stock’s market cap is $2.44 billion. The firm has a 50-day moving average price of $18.97 and a 200-day moving average price of $21.11.

Intrexon Corporation (NYSE:XON) last released its quarterly earnings results on Wednesday, August 9th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.05. The business had revenue of $54.40 million during the quarter, compared to the consensus estimate of $57.17 million. Intrexon Corporation had a negative return on equity of 19.08% and a negative net margin of 60.63%. The business’s revenue was up 3.6% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.42) EPS. On average, equities research analysts anticipate that Intrexon Corporation will post ($0.87) EPS for the current fiscal year.

Intrexon Corporation Company Profile

Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.

Want to see what other hedge funds are holding XON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intrexon Corporation (NYSE:XON).

Institutional Ownership by Quarter for Intrexon Corporation (NYSE:XON)

Receive News & Ratings for Intrexon Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.